Dat			
		Hougaard Chakera	
Ma	nuscript title: Merke	lcellekarcinom	
Ma	nuscript number (if know	າ): 01-21-0061	
are r third comr list a The f	elated to the content of your parties whose interests maitment to transparency a relationship/activity/inter	our manuscript. "Related" nay be affected by the con and does not necessarily in est, it is preferable that yo	relationships/activities/interests listed below that means any relation with for-profit or not-for-profit tent of the manuscript. Disclosure represents a dicate a bias. If you are in doubt about whether to bu do so. ps/activities/interests as they relate to the current
The a perta antih	author's relationships/acti ains to the epidemiology o hypertensive medication, e em #1 below, report all sup	f hypertension, you should even if that medication is n	defined broadly. For example, if your manuscript declare all relationships with manufacturers of ot mentioned in the manuscript. d in this manuscript without time limit. For all months.
		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
Tim	e frame: Since the initial pla	whom you have this relationship or indicate none (add rows as needed)	(e.g., if payments were made to you or to your
Tim 1	e frame: Since the initial pla All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)	whom you have this relationship or indicate none (add rows as needed)	(e.g., if payments were made to you or to your
_	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges,	whom you have this relationship or indicate none (add rows as needed) nning of the work	(e.g., if payments were made to you or to your institution)
_	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this	whom you have this relationship or indicate none (add rows as needed) nning of the work	(e.g., if payments were made to you or to your
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this	whom you have this relationship or indicate none (add rows as needed) nning of the work	(e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	whom you have this relationship or indicate none (add rows as needed) nning of the work	(e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. e frame: past 36 months Grants or contracts from any entity (if not indicated in item #1 above).	whom you have this relationship or indicate none (add rows as needed) nning of the work None None None Kræftens Bekæmpelse Innovationsfonden	(e.g., if payments were made to you or to your institution) Click TAB in last row to add extra rows Research in skin diagnostics
Tim 2	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. Grants or contracts from any entity (if not indicated	whom you have this relationship or indicate none (add rows as needed) nning of the work None None	(e.g., if payments were made to you or to your institution) Click TAB in last row to add extra rows Research in skin diagnostics

4	Consulting fees	□ None	
		Sanofi	For educational support
5	Payment or honoraria for	☐ None	
	lectures, presentations, speakers bureaus, manuscript writing or educational events	Merck and Pfeizer	Funded the venue for the 1 st and 2 nd danish MCC meeting and a 1-day educational trip to Charité University Hospital, Berlin.
6	Payment for expert testimony	⊠ None	
7	Support for attending meetings and/or travel	None Non	
	meetings and/or traver		
8	Patents planned, issued or	None	
	pending		
9	Participation on a Data	None Non	
	Safety Monitoring Board		
	or Advisory Board		
10	Leadership or fiduciary	None Non	
	role in other board,		
	society, committee or		
	advocacy group, paid or unpaid		
	anpara		
11	Stock or stock options	None Non	
12	Receipt of equipment,	None Non	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	None Non	
	financial interests		

🛛 I certify that I have answered every question and have not altered the wording of any of the questions on this form.

IMPORTANT for Ugeskrift for Læger & Danish Medical Journal

Please save/export the filled in form as PDF before submitting it to Ugeskrift for Læger or Danish Medical Journal.

Date : 6. marts 2021	
Your name:	Elizaveta Tabaksblat
Manuscript title:	Merkelcellekarcinom
Manuscript number	(if known): 01-21-0061

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
Tim	e frame: Since the initial plar	nning of the work	
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this	⊠ None	
	item.		ON LEAD IN LAND IN LAND

Click TAB in last row to add extra rows

Tim	e frame: past 36 months		
2	Grants or contracts from	None	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	None Non	

4	Consulting fees	⊠ None
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None None
6	Payment for expert testimony	None
7	Support for attending meetings and/or travel	None
8	Patents planned, issued or pending	⊠ None
9	Participation on a Data Safety Monitoring Board or Advisory Board	⊠ None
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None None
11	Stock or stock options	None
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None
13	Other financial or non-financial interests	⊠ None

 \boxtimes I certify that I have answered every question and have not altered the wording of any of the questions on this form.

IMPORTANT for Ugeskrift for Læger & Danish Medical Journal

Please save/export the filled in **form as PDF** before submitting it to Ugeskrift for Læger or Danish Medical Journal.

Date: 6. marts 2021
Your name: Lisbet Rosenkrantz Hölmich
Manuscript title: Merkelcellekarcinom
Manuscript number (if known): 01-21-0061

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
Tim	e frame: Since the initial plan	nning of the work	
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)	⊠ None	
	item.		

Click TAB in last row to add extra rows

Tim	e frame: past 36 months		
2	Grants or contracts from	None	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	None Non	

4	Consulting fees	⊠ None		
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	☐ None Merck and Pfeizer	Funded the venue for the 1 st and 2 nd danish MCC meeting and a 1-day educational trip to Charité University Hospital, Berlin.	
6	Payment for expert testimony	⊠ None		
7	Support for attending			
	meetings and/or travel	Z None		
8	Patents planned, issued or pending	None Non		
9	Participation on a Data	N None		
7	Safety Monitoring Board or Advisory Board	⊠ None		
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	⊠ None		
11	Stock or stock options	⊠ None		
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	⊠ None		
13	Other financial or non- financial interests	hospital, dept. of plasti	of research unit at Herlev and Gentofte c surgery, signed a contract with MSD (Merk rovide a report about stage II and III melanoma.	

 \boxtimes I certify that I have answered every question and have not altered the wording of any of the questions on this form.

IMPORTANT for Ugeskrift for Læger & Danish Medical Journal

PI W	ease save/export the filled in form as PDF before submitting it to Ugeskrift for Læger or Danish edical Journal.	

Date	e: 6. marts 2021		
You	r name: Morten Ladekar		
Mar	nuscript title: Merkel	cellekarcinom	
Mar	nuscript number (if known): 01-21-0061	
conter affecte bias. I The fo manus The au epider	nt of your manuscript. "Related" ed by the content of the manuscrif you are in doubt about whethe llowing questions apply to the accript only.	means any relation with for-property. Disclosure represents a color to list a relationship/activity/inthor's relationships/activities/terests should be defined broaduld declare all relationships with	s/activities/interests listed below that are related to the offit or not-for-profit third parties whose interests may be mmitment to transparency and does not necessarily indicate a nterest, it is preferable that you do so. Interests as they relate to the current Oly. For example, if your manuscript pertains to the the manufacturers of antihypertensive medication, even if that
	n #1 below, report all support for closure is the past 36 months.	the work reported in this man	uscript without time limit. For all other items, the time frame
		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
Time	e frame: Since the initial plan	ning of the work	
1	All support for the present	None Non	
	manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)		
	provision of study materials, medical writing, article processing charges,		
	provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.		Click TAB in last row to add extra rows
Time	provision of study materials, medical writing, article processing charges, etc.)		Click TAB in last row to add extra rows
Time 2	provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None	Click TAB in last row to add extra rows
	provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. e frame: past 36 months Grants or contracts from any entity (if not indicated	None None None	Click TAB in last row to add extra rows
2	provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. Grame: past 36 months Grants or contracts from any entity (if not indicated in item #1 above).		Click TAB in last row to add extra rows
2	provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. Grame: past 36 months Grants or contracts from any entity (if not indicated in item #1 above).		Click TAB in last row to add extra rows

-	D			
5	Payment or honoraria for			
	lectures, presentations, speakers bureaus, manuscript writing or educational events			
6	Payment for expert	None Non		
	testimony			
7	Support for attending	□ None		
	meetings and/or travel		Registration fee for attending medical congresses	
			paid by Pfeizer, Bayer, Roche	
8	Patents planned, issued or	None Non		
	pending	Z None		
9	Participation on a Data	■ None		
	Safety Monitoring Board or Advisory Board			
	or Advisory Board			
10	Leadership or fiduciary	□ None		
	role in other board,			
	society, committee or			
	advocacy group, paid or		National Board of Health Committee for	
	unpaid		Experimental Treatment (consultant fee)	
			Danish Medicines Council (unpaid)	
11	Stock or stock options		⊠ None	
12	Receipt of equipment.			
12	Receipt of equipment, materials, drugs, medical	⊠ None		
12	materials, drugs, medical writing, gifts or other			
12	materials, drugs, medical			
	materials, drugs, medical writing, gifts or other services	⊠ None		
12	materials, drugs, medical writing, gifts or other services Other financial or non-		Oncological department reserves as have	
	materials, drugs, medical writing, gifts or other services	⊠ None	Oncological department receives or have received payment for clinical trial conduct, in	
	materials, drugs, medical writing, gifts or other services Other financial or non-	⊠ None	received payment for clinical trial conduct, in	
	materials, drugs, medical writing, gifts or other services Other financial or non-	⊠ None	received payment for clinical trial conduct, in which I am involved, from several companies including: Roche, AstraZeneka, MSD, BMS,	
	materials, drugs, medical writing, gifts or other services Other financial or non-	⊠ None	received payment for clinical trial conduct, in which I am involved, from several companies	

 \boxtimes I certify that I have answered every question and have not altered the wording of any of the questions on this form.

IMPORTANT for Ugeskrift for Læger & Danish Medical Journal

Please save/export the filled in **form as PDF** before submitting it to Ugeskrift for Læger or Danish Medical Journal.

Date: 6. marts 2021				
Your name: Niels Junker				
Manuscript title: Merkelcellekarcinom				
Manuscript number (if known): 01-21-0061				

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
Tim	e frame: Since the initial plan	nning of the work	
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)	⊠ None	
	item.		

Click TAB in last row to add extra rows

Tim	e frame: past 36 months		
2	Grants or contracts from	None	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	None Non	

4	Consulting fees	None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	□ None Merck and Pfeizer	Funded the venue for the 1 st and 2 nd danish MCC meeting and a 1-day educational trip to Charité University Hospital, Berlin.
6	Payment for expert testimony	⊠ None	
7	Support for attending meetings and/or travel	⊠ None	
8	Patents planned, issued or pending	None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	None Non	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None	
11	Stock or stock options	None Non	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None Non	
13	Other financial or non- financial interests	None Non	

🛛 I certify that I have answered every question and have not altered the wording of any of the questions on this form.

IMPORTANT for Ugeskrift for Læger & Danish Medical Journal

Dat	e: 6. marts 2021		
You	ır name: Seppo W. Lange	er	
		cellekarcinom	
ivia	nuscript number (if known): 01-21-0061	
are re third comr list a The f	elated to the content of yo parties whose interests manitment to transparency are relationship/activity/interestions apply to	ur manuscript. "Related" ay be affected by the cont nd does not necessarily in est, it is preferable that yo	relationships/activities/interests listed below that means any relation with for-profit or not-for-profit cent of the manuscript. Disclosure represents a dicate a bias. If you are in doubt about whether to bu do so. Des/activities/interests as they relate to the current
manı	uscript only.		
perta antih	ains to the epidemiology of hypertensive medication, ev	hypertension, you should ven if that medication is n	defined broadly. For example, if your manuscript declare all relationships with manufacturers of ot mentioned in the manuscript.
	r items, the time frame for	•	d in this manuscript without time limit. For all
otne	r items, the time frame for	disclosure is the past 50 i	nontris.
		Name all entities with whom you have this relationship or indicate none (add rows as	Specifications/Comments (e.g., if payments were made to you or to your institution)
Tim	a frama: Since the initial plan	whom you have this relationship or indicate none (add rows as needed)	(e.g., if payments were made to you or to your
	e frame: Since the initial plan	whom you have this relationship or indicate none (add rows as needed) ning of the work	(e.g., if payments were made to you or to your
Tim 1	All support for the present	whom you have this relationship or indicate none (add rows as needed)	(e.g., if payments were made to you or to your
		whom you have this relationship or indicate none (add rows as needed) ning of the work	(e.g., if payments were made to you or to your
	All support for the present manuscript (e.g., funding, provision of study materials, medical writing,	whom you have this relationship or indicate none (add rows as needed) ning of the work	(e.g., if payments were made to you or to your
	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges,	whom you have this relationship or indicate none (add rows as needed) ning of the work	(e.g., if payments were made to you or to your
	All support for the present manuscript (e.g., funding, provision of study materials, medical writing,	whom you have this relationship or indicate none (add rows as needed) ning of the work	(e.g., if payments were made to you or to your
	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)	whom you have this relationship or indicate none (add rows as needed) ning of the work	(e.g., if payments were made to you or to your
	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges,	whom you have this relationship or indicate none (add rows as needed) ning of the work	(e.g., if payments were made to you or to your
	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this	whom you have this relationship or indicate none (add rows as needed) ning of the work	(e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	whom you have this relationship or indicate none (add rows as needed) ning of the work	(e.g., if payments were made to you or to your
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this	whom you have this relationship or indicate none (add rows as needed) ning of the work	(e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	whom you have this relationship or indicate none (add rows as needed) ning of the work None	(e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. e frame: past 36 months	whom you have this relationship or indicate none (add rows as needed) ning of the work None	(e.g., if payments were made to you or to your institution) Click TAB in last row to add extra rows
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	whom you have this relationship or indicate none (add rows as needed) ning of the work None	(e.g., if payments were made to you or to your institution)
Tim	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. Grants or contracts from any entity (if not indicated in item #1 above).	whom you have this relationship or indicate none (add rows as needed) Ining of the work None None	(e.g., if payments were made to you or to your institution) Click TAB in last row to add extra rows
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. Grants or contracts from any entity (if not indicated	whom you have this relationship or indicate none (add rows as needed) ning of the work None	(e.g., if payments were made to you or to your institution) Click TAB in last row to add extra rows
Tim	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. Grants or contracts from any entity (if not indicated in item #1 above).	whom you have this relationship or indicate none (add rows as needed) Ining of the work None None	(e.g., if payments were made to you or to your institution) Click TAB in last row to add extra rows

4	Consulting fees	⊠ None	
5	Payment or honoraria for	⊠ None	
	lectures, presentations,	ZI None	
	speakers bureaus,		
	manuscript writing or		
	educational events		
_	_		
6	Payment for expert	None	
	testimony		
7	Support for attending	⊠ None	
	meetings and/or travel		
8	Patents planned, issued or	None	
	pending		
9	Participation on a Data	☐ None	
	Safety Monitoring Board	Roche	Advisory Boars 2018
	or Advisory Board		7.4.100.7 204.0 2020
10	Leadership or fiduciary	None	
	role in other board, society, committee or		
	advocacy group, paid or		
	unpaid		
	1		
11	Stock or stock options	⊠ None	
12	Receipt of equipment,	⊠ None	
12	materials, drugs, medical	△ None	
	writing, gifts or other		
		İ	
	services		
	services		
13	Services Other financial or non-	⊠ None	
13	services	⊠ None	

🛛 I certify that I have answered every question and have not altered the wording of any of the questions on this form.

IMPORTANT for Ugeskrift for Læger & Danish Medical Journal

Yo	ur name:	IMON	NASE	RI
M	anuscript title: Merkel	cellekarcinom	1	
M	anuscript number (if known): 01-21-0061	N SUS	REPRESENTATION OF THE PROPERTY
thir	related to the content of you	our manuscrip hay be affecte and does not r	t. "Related" d by the con necessarily in	relationships/activities/interests listed below that means any relation with for-profit or not-for-profit tent of the manuscript. Disclosure represents a adicate a bias. If you are in doubt about whether to ou do so.
The	following questions apply nuscript only.	to the author	s relationsh	ps/activities/interests as they relate to the <u>current</u>
per	tains to the epidemiology o	f hypertensio	n, you shoul	defined broadly. For example, if your manuscript d declare all relationships with manufacturers of not mentioned in the manuscript.
n it		port for the	work reporte	ed in this manuscript without time limit. For all
	CONTRACTOR OF THE PARTY OF THE			
	Ha. A	Name all en whom you h relationship none (add n	ave this or indicate	Specifications/Comments (e.g., if payments were made to you or to your institution)
Tir	ne frame: Since the initial pla	whom you h relationship none (add re needed)	ave this or indicate ows as	(e.g., if payments were made to you or to your
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	whom you h relationship none (add re needed)	ave this or indicate ows as	(e.g., if payments were made to you or to your
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	whom you h relationship none (add re needed)	ave this or indicate ows as	(e.g., if payments were made to you or to your
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this	whom you h relationship none (add re needed)	ave this or indicate ows as	(e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	whom you h relationship none (add re needed)	ave this or indicate ows as	(e.g., if payments were made to you or to your institution)

1	Consulting fees	⊠ None	
-	Payment or honoraria for	□ None	
	lectures, presentations, speakers bureaus, manuscript writing or educational events	Merck and Pfeizer	Funded the venue for the 1 st and 2 ^{nt} danish MCC meeting and a 1-day educational trip to Charité University Hospital, Berlin.
-0	Payment for expert	⊠ None	
	testimony		
7	Support for attending	⊠ None	
	meetings and/or travel		
В	Patents planned, issued or pending	⊠ None	
9	Participation on a Data	⊠ None	
	Safety Monitoring Board or Advisory Board		
10	Leadership or fiduciary role in other board,	⊠ None	
	society, committee or advocacy group, paid or		
	unpaid		
11	Stock or stock options	⊠ None	
	THE RESERVE		12.1
12		⊠ None	
	materials, drugs, medical writing, gifts or other services		
13	Other financial or non-	⊠ None	

☑ I certify that I have answered every question and have not altered the wording of any of the questions on this form.

IMPORTANT for Ugeskrift for Læger & Danish Medical Journal Please save/export the filled in form as PDF before submitting it to Ugeskrift for Læger or Danish Medical Journal.

Dat	te: 6. marts 2021		
You	ur name:		
-		lcellekarcinom	
	nuscript number (if known		
are r third com	related to the content of your last to the content of your last to the content of	our manuscript. "Related" ay be affected by the con nd does not necessarily in	relationships/activities/interests listed below that means any relation with for-profit or not-for-profit tent of the manuscript. Disclosure represents a dicate a bias. If you are in doubt about whether to bu do so.
	following questions apply t uscript only.	o the author's relationshi	ps/activities/interests as they relate to the <u>current</u>
perta antih In ite	ains to the epidemiology of nypertensive medication, e	hypertension, you should yen if that medication is n port for the work reporte	defined broadly. For example, if your manuscript dideclare all relationships with manufacturers of not mentioned in the manuscript. d in this manuscript without time limit. For all months.
		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
Tim	e frame: Since the initial plar	nning of the work	
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	⊠ None	
			Click TAB in last row to add extra rows
Time	e frame: past 36 months	VIII STATE OF A	and the second to dud extra rows
2	Grants or contracts from any entity (if not indicated in item #1 above).	⊠ None	
3	Royalties or licenses	⊠ None	

4	Consulting fees	⊠ None		
5	Payment or honoraria for	□ None		
	lectures, presentations, speakers bureaus, manuscript writing or educational events	Merck and Pfeizer	Funded the venue for the 1 st and 2 nd danish MCC meeting and a 1-day educational trip to Charité University Hospital, Berlin.	
6	Payment for expert testimony	⊠ None		
7	Support for attending meetings and/or travel	⊠ None		
8	Patents planned, issued or pending	⊠ None		
9	Participation on a Data	⊠ None		
	Safety Monitoring Board or Advisory Board			
10	Leadership or fiduciary	⊠ None		
	role in other board, society, committee or			
	advocacy group, paid or unpaid			
11	Stock or stock options	⊠ None		
12	Receipt of equipment, materials, drugs, medical	⊠ None		
	writing, gifts or other services			
12	Other financial arras	57 61		
13	Other financial or non- financial interests	⊠ None		

I certify that I have answered every question and have not altered the wording of any of the Torben Steiniche questions on this form. Professor, MD. DMSci

Institute of Pathology Aarhus University Hospital Palle Juul-Jensens Blvd. 99 DK-8200 Aarhus N

IMPORTANT for Ugeskrift for Læger & Danish Medical Journal